Longevity Treatments: What Works, What Is Promising and What Is Hype

The most useful answer is not the most marketable one: no treatment has yet been shown to slow or reverse human aging. The FDA states that no medication has been proven to slow or reverse the aging process. That does not make longevity medicine empty. It means two different questions need different answers.

Question one is, “What lowers my risk of heart attack, stroke, preventable cancer, fracture, muscle loss or disability?” Several interventions have strong human outcome data. Question two is, “What directly modifies the biology of aging and extends healthy lifespan in an otherwise healthy person?” Rapamycin, metformin, NAD+, senolytics, plasma exchange and other geroscience strategies do not yet have a definitive clinical answer to that second question.

Clinical and editorial review: August 3, 2026. We reviewed the Spanish searches “tratamientos de longevidad” and “tratamientos antienvejecimiento que funcionan” and the English searches “longevity treatments” and “anti-aging treatments that work” on that date, then checked current guidelines, trials and official regulators. Search results frequently place aesthetics, prevention, supplements and experimental therapies on the same level. This guide ranks them by outcome, population, risk and certainty. It is educational and does not replace medical care.

Quick answer: four levels that should not be mixed

Level	What belongs here	What the evidence supports
Clinical standard	Exercise, nutrition, sleep, no smoking, less alcohol, vaccines, screening and control of blood pressure, LDL, glucose and bone health.	Reduces disease, events or disability in defined populations. This is the highest-yield foundation.
Indicated treatment	Statins, antihypertensives, GLP-1s, menopausal hormone therapy and osteoporosis drugs when appropriate.	Can improve specific outcomes when expected benefit exceeds harm. It is not universal “anti-aging”.
Promising or investigational	Geroprotective rapamycin, metformin in healthy adults, NAD+, senolytics, TPE for aging and selected HBOT protocols.	Mechanistic, biomarker or early clinical signals exist; healthspan, long-term safety or mortality evidence is missing.
Unproven / red zone	Unapproved peptides, commercial exosomes, “anti-aging” stem cells, secret blends and research-use-only products.	Benefit cannot be promised; identity, purity, immunogenicity, infection and other harms may be uncertain.

What does it mean for a longevity treatment to work?

A change in glucose, NAD+, telomere length or an epigenetic clock is not automatically a longer or better life. A convincing longevity intervention should define the population, dose, duration, comparator, meaningful endpoint, absolute and relative effect, harms and durability. Our guide to longevity biomarkers explains why a single score cannot carry that burden.

Baseline risk changes the interpretation. A 20% relative reduction matters more when 20 in 100 people are expected to have an event than when 1 in 100 is. That is why this is not a universal ranking. It is a decision map.

The highest-yield healthspan interventions do not look futuristic

Exercise: dose, strength and function

The WHO recommends at least 150-300 minutes of moderate aerobic activity each week, or 75-150 minutes vigorous, plus muscle strengthening on at least two days. Multicomponent balance work becomes especially important in older adults. This is not based on associations alone. LIFE randomized 1,635 sedentary adults aged 70-89 with functional limitations to structured moderate activity — two center sessions and three or four home sessions each week — or health education. Over 2.6 years, major mobility disability occurred in 30.1% versus 35.5%: a 5.4-point absolute difference; HR 0.82.

The prescription changes with heart disease, pain, frailty and experience. A practical base often combines walking or cycling, two or three functional strength sessions, balance and progression. Chest pain, fainting, disproportionate breathlessness or unstable disease call for assessment before HIIT.

Food, muscle, tobacco, alcohol and sleep

A Mediterranean pattern rich in vegetables, whole fruit, legumes, nuts, olive oil, fish and minimally processed food has better evidence than a supplement stack. In PREDIMED, 7,447 Spanish adults at high cardiovascular risk assigned to Mediterranean diets supplemented with extra-virgin olive oil or nuts had roughly 30% fewer relative cardiovascular events than controls. Absolute benefit depends on risk, and the trial was republished after randomization deviations were identified.

After age 65, ESPEN recommends at least 1 g protein/kg/day, with 1.0-1.2 g/kg/day often suggested for healthy older adults; kidney disease, appetite, illness and training change the target. Protein is not an anti-aging drug. It helps protect muscle. Our sarcopenia guide connects strength, function and body composition.

Smoking cessation lowers cardiovascular, lung and cancer risk and mortality even after decades of exposure. “A glass of wine for longevity” is not a defensible prescription: WHO Europe reports no safe level for cancer risk; less is safer. For sleep, the AASM/SRS consensus recommends seven or more regular hours for adults, but extra time in bed does not treat sleep apnea, chronic insomnia, restless legs or depression. Diagnose the bottleneck.

Prevention that changes outcomes

Serious preventive medicine includes correctly measured blood pressure, ApoB/LDL and cardiovascular risk, glucose/HbA1c, renal function, oral health, risk-based vaccines and evidence-based cancer screening. It does not mean ordering every test. It means choosing tests that change a decision.

SPRINT randomized 9,361 adults aged 50 or older at high cardiovascular risk, without diabetes or previous stroke, to a systolic target below 120 or below 140 mmHg. Intensive treatment reduced the main cardiovascular outcome: 1.77% versus 2.40% per year, HR 0.73, while increasing hypotension, electrolyte abnormalities and acute kidney injury. This is not a home target; it shows the value of treating the right risk in the right population.

Across 27 statin trials with 174,000 participants, each 1 mmol/L LDL reduction was associated with about 21% fewer major vascular events. Absolute benefit is larger with established atherosclerosis or higher baseline risk. A statin does not rejuvenate. It prevents some vascular disease. Vaccines and screening work through the same logic: age, history, regional guidance and shared decisions, not one premium bundle for everyone.

Indicated drugs: powerful, not universal

GLP-1s treat obesity and risk, not age

Semaglutide and other GLP-1 receptor agonists have product-specific indications for diabetes or weight management. SELECT enrolled 17,604 adults aged 45 or older with BMI ≥27, established cardiovascular disease and no diabetes. Participants received subcutaneous semaglutide 2.4 mg weekly or placebo. At 39.8 months, the cardiovascular composite occurred in 6.5% versus 8.0%: a 1.5-point absolute reduction; HR 0.80. Adverse events leading to discontinuation occurred in 16.6% versus 8.2%.

That is a meaningful clinical result, not evidence of slower aging. Nausea, vomiting, gallbladder disease, dehydration, lean-mass loss and contraindications matter. Titration is gradual, eligibility is medical, and protein, resistance training and function should be protected.

Menopausal hormone therapy

MHT is the most effective treatment for vasomotor symptoms and prevents bone loss while used. In women younger than 60 or within 10 years of menopause onset, without contraindications, the benefit-risk balance is often favorable for troublesome symptoms and bone-loss prevention. It is not prescribed to “stop aging”. Hormone type, route, uterus, migraine, thrombosis, cancer, bleeding and cardiovascular risk change the decision. Our guide to MHT and healthspan covers the clinical detail.

Decision table: effect, eligibility, limits and risk

Intervention	Goal and human evidence	Who might consider it	Risks and what it does not prove
Aerobic + resistance exercise	Standard. Reduces disability and improves fitness, strength and cardiometabolic risk. WHO dose: 150-300 moderate min + strength ≥2 days/week.	Nearly everyone, adapted for frailty, pain or disease.	Injury or events if poorly prescribed. No protocol guarantees individual years of life.
Mediterranean diet + adequate protein	Standard. PREDIMED found ≈30% fewer relative CV events in high-risk adults; protein supports muscle.	General foundation, individualized in diabetes, kidney disease, allergy or malnutrition.	Over-restriction and muscle loss. No single food rejuvenates.
Sleep, tobacco and alcohol	Standard. ≥7 regular hours; diagnose apnea/insomnia; stop smoking; reduce alcohol.	Every adult, tailored to pattern and diagnosis.	Sedatives, abrupt withdrawal or dependence need supervision. Sleep hygiene alone does not cure all insomnia.
BP, LDL, diabetes, vaccines, screening	Standard/indicated. Reduces events in people with risk or disease.	Based on age, risk, diagnosis and preferences.	Hypotension, drug adverse effects, false positives and overtreatment. More testing is not always better.
GLP-1s	Indicated in diabetes/obesity. SELECT: 6.5% vs 8.0% MACE with semaglutide 2.4 mg weekly.	People who meet an indication and can sustain follow-up.	GI effects, gallbladder, dehydration and lean mass; no proof of generalized aging slowdown.
MHT	Indicated for symptoms and bone protection in selected profiles.	Often <60 or <10 years from menopause, without contraindications.	Thrombosis, stroke, breast/endometrial considerations by regimen; not systemic rejuvenation.
Metformin	Standard for diabetes; investigational as a geroprotector in healthy adults.	Diabetes/prediabetes or another clinical indication, not age alone.	GI effects, low B12, lactic acidosis with renal risk; no healthy-adult lifespan proof.
Rapamycin	Investigational. PEARL tested 5 or 10 mg weekly for 48 weeks; visceral fat did not change and signals were exploratory.	Clinical trials, not self-prescribed longevity use.	Immunosuppression, infection, mouth ulcers, lipids, glucose and interactions; no human lifespan proof.
NAD+/NR/NMN	Investigational for healthspan. A 2026 review found 33 human studies: metabolites rise; functional results are mixed; no outcome trials of IV NAD+.	Research or an explicit clinical indication with limited expectations.	Quality, cost, tolerability and long-term safety; raising NAD+ is not rejuvenation.
Plasma exchange / TPE	Standard for specific diseases; investigational in Alzheimer’s and aging. AMBAR studied 347 patients with mild-moderate Alzheimer’s, not healthy adults.	Apheresis indication or supervised research.	Vascular access, hypotension, calcium, bleeding, infection and reactions; no healthy longevity proof.
Hyperbaric oxygen	Standard for recognized indications; investigational for longevity. One study in 35 healthy older adults used 60 sessions and measured immune-cell telomeres.	Validated HBOT indications; research if the aim is aging.	Ear/barotrauma, oxygen toxicity and claustrophobia; uncontrolled biomarkers do not prove healthspan.
Ozone therapy	Evidence depends on indication and route; no trial proves longevity.	Only a defined indication, protocol and competent team.	Route, dose and sterility change risk; pain or biomarkers cannot be extrapolated to lifespan.
Senolytics	Investigational. Small human disease-specific trials; no general longevity evidence.	Clinical trials.	Hematologic and compound-specific toxicity; a senescence marker is not an outcome.
BPC-157, MOTS-C, TB-500	Unproven for longevity. FDA’s July 2026 compounding review highlighted limited human and characterization data.	Not outside regulated research.	Impurities, aggregation, immunogenicity, identity and sterility. “Research use only” is not patient-ready.
Stem cells and exosomes	Unproven for anti-aging. FDA has approved no exosome products; approved blood-forming stem cells have narrow disease indications.	Approved cell therapy or a regulated trial.	Infection, immune reactions, tumors, contamination and delay of effective care.

How to decide before paying for an advanced treatment

1. Define the outcome. Translate “feel better” into pain, fatigue, sleep, VO₂ max, strength, weight, glucose or an event that can be tracked.
2. Match the population. A trial in Alzheimer’s disease, diabetes or wound care does not establish benefit in a healthy person.
3. Ask for dose, product and regulatory status. Name, concentration, route, frequency, manufacturer, pharmacy, sterility and approval should be transparent.
4. Quantify absolute benefit and harm. Ask how many improved, how many stopped treatment and how long follow-up lasted.
5. Set a stopping rule. If the agreed metric does not improve, adverse effects emerge or risk changes, review or stop.
6. Do not trade away the foundation. An infusion does not cancel smoking, untreated hypertension, apnea, muscle loss or overdue screening.

At Progevita, the sequence is baseline, priorities, intervention and follow-up. Medical history, medication, blood pressure, cardiometabolic labs, body composition, strength, cardiorespiratory fitness, sleep and personal goals guide the decision. Then we repeat the relevant metric, not every panel. That is what an evidence-led longevity clinic should do.

Red flags: do not relabel urgent symptoms as “aging”

Chest pain, new shortness of breath, fainting, one-sided weakness, speech difficulty, sudden severe headache, unexplained bleeding, persistent fever, unintentional weight loss, a new mass or rapid cognitive change require prompt medical assessment. So do fever after an infusion, severe vascular-access pain, neurological symptoms or a reaction to an unregulated injectable. A longevity program must not delay emergency care or conventional diagnosis.

Frequently asked questions about longevity treatments

Is there a treatment that slows aging?

None has been proven in humans. Medicine can reduce disease and functional loss associated with aging; that is not the same as reversing the whole process.

What is the best anti-aging treatment?

The one that addresses your largest modifiable risk. For one person that is smoking cessation; for another, strength and protein; for another, treating hypertension, obesity, osteoporosis, apnea or menopausal symptoms.

Do GLP-1 drugs increase longevity?

They reduce cardiovascular and other outcomes in selected populations with diabetes, obesity or established cardiovascular disease. We do not know whether they slow aging as a general mechanism, and they should not be used without an indication.

Should a healthy person take metformin or rapamycin?

Not as routine evidence-based practice today. Rapamycin remains experimental for geroprotection. Metformin should answer a metabolic or other medical indication, not age alone.

Does a lower biological age prove a treatment works?

No. It may be exploratory evidence. Practice-changing evidence needs reproducibility, a comparator, sufficient duration and a link to function, disease or survival.

How should I compare longevity clinics?

Compare who prescribes, what diagnosis is treated, evidence in that population, product and dose, monitoring, complication management, follow-up and stopping rules. Our longevity clinic checklist provides the full framework.

Conclusion: reduce risk first, explore second

The best longevity medicine in 2026 does not promise immortality. It reduces avoidable vascular and cancer risk, protects muscle, sleep, bone and brain function, treats disease when present, and reserves experimental interventions for settings where uncertainty is explained and measured.

If you want to prioritize before choosing a treatment, an assessment can identify what has evidence for your profile, what only deserves monitoring and what should be ruled out. Request a Progevita assessment with a defined clinical and functional goal.

Sources

1. FDA. Medication Health Fraud: no medication has been proven to slow or reverse aging.
2. World Health Organization. Guidelines on physical activity and sedentary behaviour. 2020.
3. Pahor M et al. LIFE trial. JAMA. 2014. PMID: 24866862.
4. Estruch R et al. PREDIMED republication. NEJM. 2018. PMID: 29897866.
5. Volkert D et al. ESPEN practical guideline: nutrition and hydration in geriatrics. 2022. PMID: 35306388.
6. AASM/SRS. Recommended sleep duration for adults. PMID: 26039963.
7. WHO Europe. Alcohol and cancer. Updated 2025.
8. SPRINT Research Group. Final report. NEJM. 2021. PMID: 34010531.
9. Cholesterol Treatment Trialists’ Collaboration. Statins in low-risk people. Lancet. 2012. PMID: 22607822.
10. Lincoff AM et al. SELECT. NEJM. 2023. DOI: 10.1056/NEJMoa2307563.
11. NAMS. Hormone therapy position statement. 2022. PMID: 35797481.
12. Moel M et al. PEARL rapamycin trial. 2025. PMID: 40188830.
13. Gallagher C, Emmanuel OO. NAD+ systematic review. 2026. PMID: 41655607.
14. Boada M et al. AMBAR plasma exchange study. 2022. PMID: 34726348.
15. Hachmo Y et al. HBOT, telomeres and immunosenescence. 2020. PMID: 33206062.
16. FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026.
17. FDA. Consumer alert on stem cells and exosomes.